Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_assertion type Assertion NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_head.
- NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_assertion description "[This understanding, taken in conjunction with the ability to produce humanized antibodies to the IL-2R subunit by genetic engineering; to arm these antibodies, as well as IL-2 itself with toxins or with alpha- and beta-emitting radionuclides; and to modulate IL-2R subunits to optimize targeting of these agents provides a rational therapeutic strategy for the treatment of IL-2R-expressing CTCL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_provenance.
- NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_assertion evidence source_evidence_literature NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_provenance.
- NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_assertion SIO_000772 14710895 NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_provenance.
- NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_assertion wasDerivedFrom befree-20140225 NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_provenance.
- NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_assertion wasGeneratedBy ECO_0000203 NP475261.RADfOtMc9bU0_UP7zBGt3-G_QhtJJjCYOaaruv2VWHTQ8130_provenance.